CLBT

Cellebrite DI Ltd.

Fundamental data last updated:May 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Technology

industry

Software - Infrastructure

Exchange

NASDAQ

County of HQ

IL

Next Earnings Date

05/14/2026

Business Summary

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation.

 


VALUATION

P/E

44.14

Market Cap ($M USD)

$3.24B

Forward P/E

14.45

PEG

0.07

PRICE TO SALES

6.82

PRICE TO BOOK

7.14

EV / EBITDA

37.58

5-Year Average P/E

Free Cash Flow Yield

4.80%

DCF Value

$6.40

Graham Number

$3.48

Price to FCF

20.84

EV to FCF

20.18

Earnings Yield

2.27%

FCF Yield

4.80%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.29

Next Year EPS Growth Estimate

$0.90

Next Year Revenue Growth Estimate

$86.34B

Return on Equity (ROE)

18.39%

FREE CASH FLOW

Operating Margin

13.98%

Debt-to-Equity

0.05

Piotroski F-Score

5

Altman Z-Score

5.38

Return on Invested Capital (ROIC)

11.68%

Current Ratio

1.56

Quick Ratio

1.54

Net Debt to EBITDA

-1.22

Interest Coverage

0.00

Gross Profit margin

84.20%

FCF PER SHARE

$0.59

REVENUE PER SHARE

$1.79

Gainseekers Quantitative Analysis

Summary

Cellebrite DI Ltd. presents a perplexing valuation scenario. Despite a DCF value significantly below its snapshot price, the market seems to expect robust growth, as evidenced by a Forward P/E of 15.13 and a remarkably low PEG ratio of 0.07, indicating potential undervaluation relative to growth. The Altman Z-score of 5.38 suggests financial stability, while an earnings yield of 2.16% raises questions about immediate returns. The stock’s valuation appears stretched when considering its Graham Number, yet its solid Return on Equity of 18.39% reflects competent management and effective capital utilization.

AI Exposure / Tech Reliance

Operating within the Software - Infrastructure industry, Cellebrite is well-positioned to leverage AI advancements. Its technological foundation allows for seamless integration of AI-driven solutions, enhancing its product offerings. This adaptability is crucial in maintaining relevance amidst rapid tech shifts.

The Bull Case

For the discerning GARP investor, Cellebrite offers compelling reasons to buy. With a robust ROIC of 11.68%, the company demonstrates efficient capital allocation. Its FCF Yield of 4.58% and a Piotroski F-Score of 5 indicate solid financial health and operational efficiency. The impressive gross profit margin of 84.20% underscores its pricing power, suggesting a strong competitive position in the market.

The Bear Case

However, the stock is not without its pitfalls. High valuation multiples, such as a Price/Book of 7.47 and Price/Sales of 7.14, suggest the stock is priced for perfection, leaving little room for error. The EV to EBITDA ratio of 39.40 further highlights potential overvaluation. Despite a low Debt/Equity ratio, the stock's proximity to its 52-week high raises concerns about technical overextension.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$20.67

Institutional Ownership %

1-Year Beta

1.15

Insider Buying % (6 Mo)

Distance to 52-Week High

57.20%

Distance to 52-Week Low

15.29%

EARNINGS SURPRISE %

-35.71%

50-DAY SMA

$13.61

200-DAY SMA

$15.95

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.